PropertyValue
?:abstract
  • Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.
?:creator
?:doi
?:doi
  • 10.1093/infdis/jiaa228
?:journal
  • J_Infect_Dis
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/c5b56e5c1e33dcf247157b735550f7d8da7a0e5c.json
?:pmcid
?:pmid
?:pmid
  • 32348485.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
?:type
?:year
  • 2020-04-29

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/x4zuv4jo>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/x4zuv4jo>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all